Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.

about

Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.

Item

http://www.wikidata.org/entity/Q41339198

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Dramatic response of CTNNB1 an ...... n combination with pemetrexed.

@en

type

Item

label

Dramatic response of CTNNB1 an ...... n combination with pemetrexed.

@en

prefLabel

Dramatic response of CTNNB1 an ...... n combination with pemetrexed.

@en

P1476

Dramatic response of CTNNB1 an ...... n combination with pemetrexed.

@en

P2093

Bin Yang

http://www.w3.org/2001/XMLSchema#string

Dewei Zhao

http://www.w3.org/2001/XMLSchema#string

Lai Wei

http://www.w3.org/2001/XMLSchema#string

Lizhi Wang

http://www.w3.org/2001/XMLSchema#string

Meiyi Wang

http://www.w3.org/2001/XMLSchema#string

Weili Lu

http://www.w3.org/2001/XMLSchema#string

Xuejun Kong

http://www.w3.org/2001/XMLSchema#string

Yan Ding

http://www.w3.org/2001/XMLSchema#string

Zhiqiang Wang

http://www.w3.org/2001/XMLSchema#string

Ziye Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.

Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion

Treatment and prognosis of squamous cell carcinoma of the external auditory canal and middle ear: a multi-institutional retrospective review of 87 patients.

Outcomes following temporal bone resection.

The misdiagnosis of external auditory canal carcinoma.

P304

57898-57904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.18632/ONCOTARGET.19649

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28915721

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5593693

http://www.w3.org/2001/XMLSchema#string